Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-02-27 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2016年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2016 年度业绩快报' which translates to '2016 Annual Performance Express Report' or '2016 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2016, including revenue, profit, net profit attributable to shareholders, earnings per share, and other financial metrics. The document explicitly states that the data is preliminary, internally audited but not audited by an external accounting firm, and may differ from the final annual report. It also includes explanations of business performance and reasons for differences from previous forecasts. The document length is 2132 characters, which is relatively short and typical for an earnings release or performance quick report rather than a full annual report. There is no indication that this is a full Annual Report (10-K) or a detailed Management Discussion & Analysis (MDA). It is not a report publication announcement since it contains actual financial data and explanations. Therefore, the document fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2016
2017-02-27 Chinese
关于公司控股子公司贵州宏奇药业有限公司变更企业名称及增资完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the name and capital increase registration of a subsidiary company, Guizhou Hongqi Pharmaceutical Co., Ltd., now renamed to Kuaihua Pharmaceutical Group (Guizhou) Hongqi Co., Ltd. It details the acquisition of shares, capital injection, and the updated business license information. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a capital and registration change, not a full financial report or regulatory filing of financial results. It fits best under Capital/Financing Update (CAP) as it concerns capital injection and ownership changes in a subsidiary.
2017-02-16 Chinese
独立董事关于第二届董事会第三十四次会议相关议案之独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting agenda regarding the company's acquisition and capital increase in another company. It discusses the transaction details, compliance with regulations, and the independent directors' approval. This is a typical example of Board/Management Information (MANG) as it relates to board decisions and management actions rather than a full report or announcement of financial results.
2017-01-18 Chinese
关于使用自有资金收购贵州宏奇药业有限公司股权并对其增资相关事项公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of a 55.9% equity stake in Guizhou Hongqi Pharmaceutical Co., Ltd. by Kuaihua Pharmaceutical Group Co., Ltd., including the use of self-owned funds for the acquisition and subsequent capital increase. It includes specifics about the transaction, parties involved, shareholding structure before and after the transaction, financial data of the target company, risk disclosures, independent directors' opinions, and related contracts. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital/financing transaction involving equity acquisition and capital increase. It does not fit the definitions of merger & acquisition filings (which are more about merger proposals or tender offers), but it clearly relates to financing and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6137 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2017-01-18 Chinese
第二届董事会第三十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 葵花药业集团股份有限公司. It details the approval of a transaction involving the acquisition of equity in another company and subsequent capital increase. The document includes voting results and mentions independent directors' opinions. There are no financial statements or detailed financial performance data, nor is it a transcript or presentation. It is clearly an announcement of board decisions, specifically about a capital investment and acquisition. Therefore, it fits best under 'Board/Management Information' (MANG), which covers announcements of changes or decisions by the board of directors.
2017-01-18 Chinese
东海证券股份有限公司关于公司2016年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2016年度现场检查报告" which translates to "2016 Annual On-site Inspection Report" by Donghai Securities Co., Ltd. for Kuaihua Pharmaceutical Group Co., Ltd. The content includes detailed inspection items such as corporate governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, and fulfillment of commitments. It involves examination of company documents, interviews, and verification of compliance with regulations. The document is a detailed inspection report rather than a general annual report or audit report. It is not a brief announcement or a certification letter. The nature of the document fits best with an Audit Report / Information (AR) category as it is a standalone inspection report focusing on compliance, internal controls, and governance, but not a full annual report or financial statement. Therefore, the classification is AR with high confidence. FY 2016
2017-01-03 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.